No Benefit of Colchicine in Large MIs: CLEAR SYNERGY Trial
Several randomized trials have shown reductions in MACE with colchicine in the treatment of coronary artery disease. The CLEAR SYNERGY (OASIS 9) trial showed that... Read more.
ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction
KEY POINTS: In this prespecified exploratory analysis of the AEGIS-II trial, the authors compare rates of recurrent myocardial infarction, stroke, and cardiovascular... Read more.
Apolipoprotein A-I infusions Lowers Risk of Recurrent CV Events in Patients With Baseline LDL-C ≥100 mg/dL
KEY POINTS: In this exploratory analysis of the AEGIS-II randomized control trial, the authors compare the rates of stroke, myocardial infarction and death at 90... Read more.
ECLS-SHOCK: At One Year, ECMO Does Not Reduce Mortality in Acute MI-Related Cardiogenic Shock
Key Points: The 30-day ECLS SHOCK study demonstrated no benefit to up-front ECLS in the reduction of 30-day mortality in acute, infarct-related cardiogenic shock.... Read more.
REC-CAGEFREE I: Drug Coated Balloon Fails To Achieve Non-Inferiority vs DES For De Novo Coronary Lesions
Key Points Drug-eluting stents are the standard of care for percutaneous coronary intervention of de novo coronary lesions but nevertheless have a risk of stent... Read more.
Plozasiran Lowered Triglyceride Levels and Pancreatitis in Persistent Chylomicronemia: PALISADE
Key Points: Familial chylomicronemia syndrome (FCS) is a clinically or genetically defined syndrome of extremely high plasma triglycerides due to failure of clearance... Read more.
Bailout GP IIb/IIIa inhibition in AMI with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO: The REVERSE-FLOW trial
Key Points: Though primary PCI for coronary obstruction is first-line therapy in acute myocardial infarction (AMI), many patients experience impaired myocardial... Read more.
AZALEA-TIMI 71 Sub-study: Periprocedural Bleeding Risk Very Low and Similar With Long-acting Factor XI Inhibitor Abelacimab vs Rivaroxaban
Key Points: Factor XI inhibitors have the potential to reduce thromboembolic events while minimizing major bleeding risks. Invasive procedures are frequent among... Read more.
De-escalation to Ticagrelor Monotherapy Beneficial in Ischemic Events and Bleeding vs 12 months of DAPT: a Systematic Review and Individual Patient-Level Meta-analysis
KEY POINTS: Ticagrelor monotherapy was found to be non-inferior to 12 months of dual-antiplatelet therapy (DAPT) regarding major cardiovascular and cerebrovascular... Read more.
Microvascular Resistance Reserve as a Potential Predictor of Angina in Moderate Coronary Stenoses.
Key Points: The Microvascular Resistance Reserve (MRR), a novel measurement, assess the vasodilator reserve capacity of the coronary microvasculature while eliminating... Read more.